MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyag032

Медицинская библиотека · The oncologist · 2026

Efficacy of neoadjuvant endocrine therapy with CDK4/6 inhibitors in locally advanced breast cancer.

Zhang Mengqi, Li Mingxiao, Zhou Shihan, Jiang Mingxia, Liu Jiaxuan, Yang Xue, Qin Ling, Abudureheiyimu Nilupai, Shi Xiuqing, Li Lixi, Li Fengjuan, Guan Xiuwen, Ma Fei, Xu Binghe, Li Qiao

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Neoadjuvant treatment for hormone receptor (HR)-positive breast cancer remains limited, particularly for tumors that are insensitive to neoadjuvant chemotherapy. This study aims to compare the efficacy of neoadjuvant endocrine therapy combined with CDK4/6 inhibitors to that of traditional neoadjuvant chemotherapy.

PATIENTS AND

METHODS

A total of 49 patients receiving neoadjuvant endocrine therapy plus CDK4/6 inhibitors and 210 receiving neoadjuvant chemotherapy were enrolled. Magnetic resonance imaging was performed to assess tumor responses every 2-3 cycles of treatment. Propensity score matching (PSM) was performed to balance baseline characteristics.

RESULTS

Both before and after PSM, the objective response rate (ORR) in the endocrine therapy group was comparable to that of the traditional chemotherapy group. After matching, the ORR was 64.6% (95% CI, 49.5-77.8) in the endocrine group and 56.3% (95% CI, 41.2-70.5) in the chemotherapy group (P = .532). A higher proportion of patients in the endocrine group achieved a pathological complete or near-complete response (Miller-Payne grades 4-5, 13.5% vs 10.4%) and post-treatment Ki67 < 5%, indicating a potential long-term benefit. Patients with ≥30% regression in maximal tumor diameter after 2 cycles of chemotherapy were considered chemotherapy sensitive. Among patients with tumors less sensitive to chemotherapy, sequential treatment with neoadjuvant endocrine therapy plus CDK4/6 inhibitors significantly improved ORR (61.8% vs 32.4%, P = .028) and was associated with greater Ki67 reduction and improved Miller-Payne grades.

CONCLUSION

Neoadjuvant endocrine therapy is a promising alternative for HR-positive breast cancer, especially for patients with poor responses to chemotherapy.

Для цитирования: Zhang Mengqi, Li Mingxiao, Zhou Shihan, Jiang Mingxia, Liu Jiaxuan, Yang Xue, Qin Ling, Abudureheiyimu Nilupai, Shi Xiuqing, Li Lixi, Li Fengjuan, Guan Xiuwen, Ma Fei, Xu Binghe, Li Qiao. Efficacy of neoadjuvant endocrine therapy with CDK4/6 inhibitors in locally advanced breast cancer.. The oncologist. 2026. DOI: 10.1093/oncolo/oyag032.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.